8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have ...
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...
1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...
31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...
27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in ...
25 January 2023 - Drugs regulator recommends eptinezumab for adults when three previous treatments have failed. ...
19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...
19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy. ...
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has ...